Generation Bio Co. (NASDAQ:GBIO – Get Rating) Director Charles A. Rowland, Jr. purchased 18,784 shares of the company’s stock in a transaction on Tuesday, September 13th. The shares were bought at an average price of $5.20 per share, with a total value of $97,676.80. Following the completion of the transaction, the director now owns 119,819 shares of the company’s stock, valued at $623,058.80. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Generation Bio Stock Up 3.0 %
Generation Bio stock traded up $0.16 during trading on Thursday, reaching $5.45. The stock had a trading volume of 144,861 shares, compared to its average volume of 411,961. Generation Bio Co. has a 52-week low of $3.96 and a 52-week high of $27.32. The business has a 50 day moving average price of $6.47 and a 200 day moving average price of $6.36.
Generation Bio (NASDAQ:GBIO – Get Rating) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.03). As a group, research analysts forecast that Generation Bio Co. will post -2.63 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the company. Amalgamated Bank purchased a new stake in Generation Bio in the 1st quarter valued at $52,000. Quantbot Technologies LP raised its position in Generation Bio by 2,566.7% in the 1st quarter. Quantbot Technologies LP now owns 8,000 shares of the company’s stock valued at $58,000 after purchasing an additional 7,700 shares during the last quarter. UBS Group AG raised its position in Generation Bio by 63.1% in the 2nd quarter. UBS Group AG now owns 10,077 shares of the company’s stock valued at $66,000 after purchasing an additional 3,900 shares during the last quarter. Prelude Capital Management LLC purchased a new stake in Generation Bio in the 1st quarter valued at $74,000. Finally, Arizona State Retirement System purchased a new stake in Generation Bio in the 2nd quarter valued at $76,000. Hedge funds and other institutional investors own 93.89% of the company’s stock.
Analyst Ratings Changes
GBIO has been the subject of a number of research reports. Wedbush restated an “outperform” rating and issued a $24.00 price objective on shares of Generation Bio in a report on Friday, August 5th. Needham & Company LLC dropped their price objective on shares of Generation Bio from $27.00 to $23.00 and set a “buy” rating for the company in a report on Friday, August 5th. Finally, JMP Securities lifted their price objective on shares of Generation Bio from $10.00 to $11.00 and gave the company a “market outperform” rating in a report on Monday, August 8th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $19.33.
About Generation Bio
Generation Bio Co, a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology.